title: Annual public health and economic benefits of seasonal influenza vaccination: a European estimate.
abstract: BACKGROUND
  Vaccination is currently the most effective means of preventing influenza infection. Yet evidence of vaccine performance, and the impact and value of seasonal influenza vaccination across risk groups and between seasons, continue to generate much discussion. Moreover, vaccination coverage is below recommended levels.
  
  
  METHODS
  A model was generated to assess the annual public health benefits and economic importance of influenza vaccination in 5 WHO recommended vaccination target groups (children 6 - 23 months of age; persons with underlying chronic health conditions; pregnant women; health care workers; and, the elderly, 65 years of age) in 27 countries of the European Union. Model estimations were based on standard calculation methods, conservative assumptions, age-based and country-specific data.
  
  
  RESULTS
  Out of approximately 180 million Europeans for whom influenza vaccination is recommended, only about 80 million persons are vaccinated. Seasonal influenza vaccination currently prevents an annual average of between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths. To reach the 75% vaccination coverage target set by the EU Council Recommendation in 2009, an additional 57.4 million person would need to be vaccinated in the elderly and other risk groups. By achieving the 75% target rate set in EU-27 countries, average annual influenza- related events averted would increase from current levels to an additional +1.6 to +1.7 million cases, +23,800 to +31,400 hospitalization, +9,800 to +14,300 deaths, +678,500 to +767,800 physician visits, and +883,800 to +1,015,100 lost days of work yearly. Influenza-related costs averted because of vaccination would increase by an additional + €190 to + €226 million yearly, in vaccination target groups.
  
  
  CONCLUSIONS
  Full implementation of current influenza vaccination recommendations of 75% vaccination coverage rate (VCR) in Europe by the 2014-2015 influenza season could immediately reduce an important public health and economic burden.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Preaud
authors.forename: Laure
authors.initials: L
authors.lastname: Durand
authors.forename: Bérengère
authors.initials: B
authors.lastname: Macabeo
authors.forename: Norbert
authors.initials: N
authors.lastname: Farkas
authors.forename: Brigitte
authors.initials: B
authors.lastname: Sloesen
authors.forename: Abraham
authors.initials: A
authors.lastname: Palache
authors.forename: Francis
authors.initials: F
authors.lastname: Shupo
authors.affiliation: Sanofi Pasteur MSD, 162 av Jean Jaures, Lyon 69367, France. ssamson@spmsd.com.
authors.forename: Sandrine I
authors.initials: SI
authors.lastname: Samson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005060:Europe; D005260:Female; D006801:Humans; D007223:Infant; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000191:economics / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011634:Public Health; D012621:Seasons; D014611:Vaccination
chemical_list: D007252:Influenza Vaccines
references.citation: Euro Surveill. 2008 Oct 23;13(43):
references.pmid: 18947524
references.citation: Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
references.pmid: 23210147
references.citation: Eur Respir J. 2007 Dec;30(6):1158-66
references.pmid: 17715167
references.citation: J Infect. 2009 Jun;58(6):446-58
references.pmid: 19446340
references.citation: Clin Infect Dis. 2012 Oct;55(7):951-9
references.pmid: 22843783
references.citation: Cochrane Database Syst Rev. 2012 Aug 15;(8):CD004879
references.pmid: 22895945
references.citation: BMJ. 2011 Jan 25;344:d7901
references.pmid: 22277542
references.citation: Cochrane Database Syst Rev. 2010 Jul 07;(7):CD001269
references.pmid: 20614424
references.citation: Eur J Epidemiol. 2005;20(4):365-71
references.pmid: 15971510
references.citation: Euro Surveill. 2013 Jan 31;18(5):
references.pmid: 23399425
references.citation: PLoS One. 2013 Jun 19;8(6):e66312
references.pmid: 23840439
references.citation: Euro Surveill. 2010 Nov 04;15(44):
references.pmid: 21087586
references.citation: Emerg Themes Epidemiol. 2005 Jun 21;2:6
references.pmid: 15969758
references.citation: PLoS One. 2011;6(11):e27622
references.pmid: 22110695
references.citation: Gac Sanit. 2012 Jul-Aug;26(4):325-9
references.pmid: 22284214
references.citation: Vaccine. 2006 Nov 17;24(47-48):6812-22
references.pmid: 17034909
references.citation: Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876
references.pmid: 20166072
references.citation: J Infect. 2007 Jun;54(6):530-8
references.pmid: 17097147
references.citation: Vaccine. 2013 Jan 30;31(6):927-42
references.pmid: 23246550
references.citation: Hum Vaccin Immunother. 2012 Mar;8(3):328-35
references.pmid: 22327498
references.citation: Am J Prev Med. 2006 Jul;31(1):72-9
references.pmid: 16777545
references.citation: Arch Intern Med. 2002 Sep 9;162(16):1842-8
references.pmid: 12196082
references.citation: Vaccine. 2006 Jan 30;24(5):622-8
references.pmid: 16169638
references.citation: Lancet Infect Dis. 2013 Jan;13(1):7-9
references.pmid: 23257219
references.citation: Euro Surveill. 2008 Oct 09;13(41):
references.pmid: 18926107
references.citation: Clin Drug Investig. 2012 Feb 1;32(2):73-85
references.pmid: 22201294
references.citation: Emerg Infect Dis. 2007 May;13(5):694-9
references.pmid: 17553246
references.citation: Health Syst Transit. 2012;14(5):1-159
references.pmid: 22894859
references.citation: Rev Esp Salud Publica. 2011 Jan-Feb;85(1):19-31
references.pmid: 21750839
references.citation: Epidemiol Infect. 2010 Nov;138(11):1559-68
references.pmid: 20334732
references.citation: PLoS One. 2012;7(2):e31696
references.pmid: 22348122